Response to

Other Title
'Correspondence on 'Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial'' by Zhao and Huang
Journal
Annals of the Rheumatic Diseases
Date Issued
2023-07-01
Author(s)
DOI
URI
Type
journal article